Modality
Degrader
MOA
CAR-T BCMA
Target
FcRn
Pathway
Proteasome
MSAS
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
Mar 2019
→ Mar 2029
Phase 2Current
NCT03161357
868 pts·AS
2019-03→2029-03·Completed
NCT05905540
1,797 pts·AS
2022-12→TBD·Recruiting
2,665 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-062.9y awayPh3 Readout· AS
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Complet…
P2/3
Recruit…
Catalysts
Ph3 Readout
2029-03-06 · 2.9y away
AS
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03161357 | Phase 2/3 | AS | Completed | 868 | FEV1 |
| NCT05905540 | Phase 2/3 | AS | Recruiting | 1797 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |